Alpha-2-adrenergic agonists for improving vision
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- BAUSCH & LOMB IRELAND LIMITED
- Filing Date
- 2026-05-29
- Publication Date
- 2026-07-10
Abstract
Description
Abstract This paper discloses a method for improving visual acuity, visual field and other visual function indicators, which involves administering an α2-adrenergic agonist to mammals in need.
Claims
PCT Patent Application W5810.10001WO01 CLAIMS 1. A method of improving visual acuity comprising administering an alpha-2 adrenergic agonist to a mammal in need thereof.
2. A method of improving visual acuity under low-luminance lighting conditions comprising administering an alpha-2 adrenergic agonist to a mammal in need thereof.
3. A method of improving visual field comprising administering an alpha-2 adrenergic agonist to a mammal in need thereof.
4. The method of claim 1, 2, or 3, wherein the alpha-2 adrenergic agonist is a compound that does not have a clinically relevant effect upon pupil size when administered in an amount effective to improve visual acuity or visual field.
5. A method of improving or delaying progressive loss of a measure of visual function under normal lighting or low-luminance lighting conditions without reducing pupil size, comprising administering an alpha-2 adrenergic agonist to a mammal in need thereof, wherein an improvement or delay of progressive loss of a measure of visual function under normal lighting or low-luminance lighting conditions is experienced by the mammal without a reduction in pupil size.
6. The method of claim 5, wherein the measure of visual function is contrast sensitivity.
7. The method of claim 5, wherein the measure of visual function is color vision.
8. The method of claim 5, wherein the measure of visual function is performance of vision related tasks.
9. A method of improving visual acuity or visual field without reducing pupil size, comprising administering an alpha-2 adrenergic agonist to a mammal, wherein an improvement in visual acuity or visual field is experienced by the mammal without a clinically meaningful reduction in pupil size.
10. The method of claim 9, wherein the mammal has normal vision.
11. The method of claim 9, wherein the human being has myopia.
12. The method of any one of claims 1-10, wherein the alpha-2 adrenergic agonist is (S)- (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol, or a pharmaceutically acceptable salt or an ester thereof.
13. The method of claim 11, wherein the alpha-2 adrenergic agonist is [3-[(1S)-1-(1H- imidazole-5-yl)ethyl]-2-methylphenyl]methyl-2,2-dimethylpropanoate.
14. The method of any one of claims 1-13, wherein the mammal is a human being.PCT Patent Application W5810.10001WO01 15. The method of claim 14, wherein the human being has glaucoma.
16. The method of claim 14, wherein the human being has ocular hypertension.
17. The method of claim 14, wherein the human being has age-related macular degeneration.
18. The method of claim 14, wherein the human being has a retinal condition associated with decreased low-luminance visual acuity.
19. The method of claim 14, wherein the human being has geographic atrophy.
20. The method of any preceding claim, wherein the improvement in visual function, visual acuity, or visual field is experienced within two weeks of receiving the first dose of the alpha-2 adrenergic agonist.